Recruiting
The Clinical Trial of Tamibarotene for Patients With HFpEF (RELIEF Trial)
NCT07855692· Phase 2· Nagoya University· Source
Contact: Matsue Yuya, MD, PhD
Recruiting
A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).
NCT07867080· Phase 3· 4D Molecular Therapeutics· Source
Contact: 4DMT Patient Advocacy
Recruiting
A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer
NCT07766018· Phase 2· Stemline Therapeutics, Inc.· Source
Contact: Junichiro Watanabe (principal investigator)
Recruiting
A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
NCT07470879· Phase 2· Pfizer· Source
Recruiting
Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure
NCT07397650· Phase 4· Juntendo University· Source
Contact: Yuya Matsue
Recruiting
DALY II Japan/MB-CART2019.1 for DLBCL
NCT07288879· Phase 2· Miltenyi Biomedicine GmbH· Source
Contact: Clinical Trial Manager
Recruiting
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06793215· Phase 3· Hoffmann-La Roche· Source
Recruiting
Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial
NCT07111559· Phase 4· Nippon Medical School· Source
Contact: Nobukazu Miyamoto
Active, not recruiting
P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk
NCT06468033· Phase 3· PharmaEssentia· Source
Active, not recruiting
A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy
NCT06848231· Phase 2· Dasher Neuroscience Inc.· Source
Active, not recruiting
A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)
NCT06730061· Phase 3· Ipsen· Source
Active, not recruiting
Phase 2b Open-Label Repeat Kidney Biopsy Study
NCT06740526· Phase 2· Otsuka Pharmaceutical Development & Commercialization, Inc.· Source
Recruiting
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies.
NCT06812104· Phase 1· Kyowa Kirin Co., Ltd.· Source
Contact: Masayoshi Noshiro
Active, not recruiting
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
NCT06531824· Phase 3· Boehringer Ingelheim· Source
Active, not recruiting
A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).
NCT06412666· Phase 2/3· Cytokinetics· Source
Recruiting
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
NCT06321302· Phase 2· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Active, not recruiting
Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
NCT06253663· Phase 2· Kite, A Gilead Company· Source
Recruiting
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
NCT05923073· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma
NCT05572515· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
NCT05555732· Phase 3· Daiichi Sankyo· Source
Active, not recruiting
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926· Hoffmann-La Roche· Source
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
NCT05170204· Phase 3· Hoffmann-La Roche· Source
Recruiting
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
NCT05392764· Phase 3· Juntendo University· Source
Contact: Yuya Matsue
Active, not recruiting
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
NCT05306340· Phase 3· Genentech, Inc.· Source
Recruiting
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
NCT05076175· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Takahiro Kudo, Site 0010
Active, not recruiting
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
NCT04975308· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
NCT04680052· Phase 3· Incyte Corporation· Source
Active, not recruiting
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
NCT04273945· Phase 3· Actelion· Source
Recruiting
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
NCT04176198· Phase 1/2· Sumitomo Pharma America, Inc.· Source
Contact: Shuichi Shirane, MD
Active, not recruiting
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
NCT03767244· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
NCT03456076· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
Observation of Clinical Routine Care for Heart Failure Patients Implanted With BIOTRONIK CRT Devices
NCT03366545· Biotronik SE & Co. KG· Source
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03178552· Phase 2/3· Hoffmann-La Roche· Source
Active, not recruiting
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734· Phase 3· Swedish Orphan Biovitrum· Source
Active, not recruiting
Japanese Idiopathic Interstitial Pneumonias Registry
NCT03041623· North East Japan Study Group· Source
Active, not recruiting
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
NCT02411448· Phase 3· Eli Lilly and Company· Source